cell and gene therapy Archives -

How-cell-and-gene-therapies-are-transforming-the-pace-of-deal-making

Market Access/ Oncology/ R&D/ Views & Analysis/ Views and analysis

New Cell & Gene Therapy Collective seeks to boost UK adoption

George Underwood Astellas, bluebird bio, BMS, Cell & Gene Collective, cell and gene therapy, cell therapy, gene therapy, Gilead, Kite, Novartis, UK 0 Comment

The UK has been a global leader in introducing cell and gene therapies that can potentially transform the

New Cell & Gene Therapy Collective seeks to boost UK adoption

https://pharmaphorum.com/views-and-analysis/new-cell-gene-therapy-collective-seeks-to-boost-uk-adoption/

R&D/ Views & Analysis/ Views and analysis

Gene editing: beyond the hype

George Underwood CAR, CAR-Tregs, cell and gene therapy, cell therapy, CRISPR, gene editing, gene therapy, JP Morgan, Sangamo 0 Comment

Genome editing is an exciting but still nascent field, and companies in the area face as many obstacles

Gene editing: beyond the hype

https://pharmaphorum.com/r-d/views-analysis-r-d/genome-editing-sangamo-beyond-the-hype/

engineering and genetic editing through the Crispr technique. DNA chain breaking down. 3D rendering

News/ News/ R&D

Bayer buys cell & gene therapy firm AskBio for $4 billion

George Underwood AskBio, Asklepios BioPharmaceutical, Bayer, cell and gene therapy, cell therapy, gene therapy, M&A 0 Comment

Bayer is making clear its ambitions in cell and gene therapy with a $4 billion acquisition of US

Bayer buys cell & gene therapy firm AskBio for $4 billion

https://pharmaphorum.com/news/bayer-extends-reach-in-cell-gene-therapy-with-askbio-acquisition/

Market Access/ Sales and Marketing/ Views & Analysis/ Views & Analysis/ Views and analysis

Preparing for an influx of cell and gene therapy approvals

mike.hammerton@pharmaphorum.com CAR T, cell and gene therapy, cell therapy, gene therapy 0 Comment

Cell and gene therapies offer some of the most groundbreaking advancements in patient care the pharma industry has

Preparing for an influx of cell and gene therapy approvals

https://pharmaphorum.com/views-analysis-sales-marketing/preparing-influx-cell-gene-therapy-approvals/

News/ News/ News/ Oncology/ R&D/ Top stories

UK accounts for 12% of cell and gene therapy trials – report

Richard Staines cell and gene therapy, Oncology, R&D 0 Comment

The UK accounts for over 12% of global cell and gene therapy clinical trials, according to new data

UK accounts for 12% of cell and gene therapy trials – report

https://pharmaphorum.com/news/uk-accounts-for-12-of-cell-and-gene-therapy-trials-report/

R&D/ Views & Analysis/ Views and analysis

Will cell and gene therapies disrupt reimbursement?

Dominic Tyer cell and gene therapy, cell therapy, Deep Dive: Disruptive Technologies, gene therapy, Kymriah, Luxturna, PhRMA, Yescarta 0 Comment

Cell and gene therapies could prove disruptive in terms of the life-changing benefits they could bring to people

Will cell and gene therapies disrupt reimbursement?

https://pharmaphorum.com/r-d/cell-gene-therapy-reimbursement/

News/ News/ R&D/ R&D/ Top stories

Spectacular results for bluebird’s gene therapy in thalassemia

Andrew McConaghie bluebird bio, cell and gene therapy 0 Comment

Patients with the rare blood disorders transfusion-dependent β-thalassemia (TDT) have shown spectacular results in clinical trials of bluebird

Spectacular results for bluebird’s gene therapy in thalassemia

https://pharmaphorum.com/news/spectacular-results-for-bluebirds-gene-therapy-in-thalassemia/

Oncology/ R&D/ Views & Analysis/ Views and analysis

Kite and Sangamo come together in $3bn cancer gene editing alliance

Andrew McConaghie cell and gene therapy, gene editing, Gilead, Kite, Sangamo 0 Comment

Two pioneers in the parallel technologies of cell therapy and gene therapy have come together in an ambitious

Kite and Sangamo come together in $3bn cancer gene editing alliance

https://pharmaphorum.com/views-analysis-oncology/kite-sangamo-come-together-3bn-cancer-gene-editing-alliance/

Cancer/ News/ R&D/ Top stories

Novartis snaps up ex-US partnership with Spark on gene therapy

Andrew McConaghie cell and gene therapy, Luxturna, Novartis, Spark Therapeutics 0 Comment

I was at Novartis headquarters in Basel yesterday for the company’s Q4 results, and my burning question was

Novartis snaps up ex-US partnership with Spark on gene therapy

https://pharmaphorum.com/news/novartis-snaps-ex-us-partnership-spark-gene-therapy/

Trending

cell and gene therapy

Login